BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29183632)

  • 1. Recommendations for perioperative management of new pharmacological antifibrotic therapy in idiopathic pulmonary fibrosis.
    González Larrocha O; Romero Rojano P; Ortega Mera U; Arízaga Maguregui A
    Rev Esp Anestesiol Reanim (Engl Ed); 2018 Mar; 65(3):178-179. PubMed ID: 29183632
    [No Abstract]   [Full Text] [Related]  

  • 2. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 3. Two therapies now available for idiopathic pulmonary fibrosis.
    Morrow T
    Manag Care; 2014 Dec; 23(12):47-8. PubMed ID: 25939185
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antifibrotic treatment].
    von der Beck D; Löh B; Drakopanagiotakis F; Markart P; Günther A
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2523-5. PubMed ID: 25423462
    [No Abstract]   [Full Text] [Related]  

  • 5. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 6. Hot off the breath: A big step forward for idiopathic pulmonary fibrosis.
    Ryerson CJ; Collard HR
    Thorax; 2014 Sep; 69(9):791-2. PubMed ID: 24996636
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel treatments for idiopathic pulmonary fibrosis.
    Spagnolo P
    Am J Med; 2015 May; 128(5):447-9. PubMed ID: 25613299
    [No Abstract]   [Full Text] [Related]  

  • 8. New guideline on treatment of idiopathic pulmonary fibrosis.
    Spagnolo P; Bonella F; Maher TM
    Lancet Respir Med; 2015 Sep; 3(9):e31-e32. PubMed ID: 26380887
    [No Abstract]   [Full Text] [Related]  

  • 9. Update in Interstitial Lung Disease 2014.
    Belloli EA; Martinez FJ; Flaherty KR
    Am J Respir Crit Care Med; 2015 Sep; 192(5):538-43. PubMed ID: 26561676
    [No Abstract]   [Full Text] [Related]  

  • 10. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
    Ahluwalia N; Shea BS; Tager AM
    Am J Respir Crit Care Med; 2014 Oct; 190(8):867-78. PubMed ID: 25090037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating new treatment options.
    Nathan SD
    Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic pulmonary fibrosis: the turning point is now!
    Funke M; Geiser T
    Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic advances in idiopathic pulmonary fibrosis.
    George G; Vaid U; Summer R
    Clin Pharmacol Ther; 2016 Jan; 99(1):30-2. PubMed ID: 26502087
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trial research in focus: why do so many clinical trials fail in IPF?
    Spagnolo P; Maher TM
    Lancet Respir Med; 2017 May; 5(5):372-374. PubMed ID: 28412184
    [No Abstract]   [Full Text] [Related]  

  • 15. 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.
    Surolia R; Li FJ; Wang Z; Li H; Liu G; Zhou Y; Luckhardt T; Bae S; Liu RM; Rangarajan S; de Andrade J; Thannickal VJ; Antony VB
    JCI Insight; 2017 Jan; 2(2):e91377. PubMed ID: 28138565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current approaches to the management of idiopathic pulmonary fibrosis.
    Raghu G; Richeldi L
    Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis].
    Tokura T; Oku H; Tsukamoto Y
    Nihon Yakurigaku Zasshi; 2009 Aug; 134(2):97-104. PubMed ID: 19672005
    [No Abstract]   [Full Text] [Related]  

  • 20. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.